Ex-Div Reminder for Clough Global Equity Fund (GLQ)

Looking at the universe of stocks we cover at Dividend Channel, on 11/14/14, Clough Global Equity Fund (GLQ) will trade ex-dividend, for its monthly dividend of $0.105, payable on 11/26/14. As a percentage of GLQ's recent stock price of $14.23, this dividend works out to approximately 0.74%, so look for shares of Clough Global Equity Fund to trade 0.74% lower — all else being equal — when GLQ shares open for trading on 11/14/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for GLQ, showing historical dividends prior to the most recent $0.105 declared by Clough Global Equity Fund:

GLQ+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from GLQ is likely to continue, and whether the current estimated yield of 8.85% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of GLQ shares, versus its 200 day moving average:

Clough Global Equity Fund 200 Day Moving Average Chart

Looking at the chart above, GLQ's low point in its 52 week range is $12.63 per share, with $15.96 as the 52 week high point — that compares with a last trade of $14.26.

In Wednesday trading, Clough Global Equity Fund shares are currently off about 0.6% on the day.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says